|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-2-21
|
|
pubmed:abstractText |
Lamivudine (3TC) therapy can cause the emergence of M1841/V. Previous studies suggest a higher fidelity of the mutant reverse transcriptase and lower replication capacity of the mutant virus. No data exist from clinical comparative studies evaluating the benefit of M1841/V in patients receiving combination antiretroviral therapy (cART).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1359-6535
|
|
pubmed:author |
pubmed-author:BruunJohan NJN,
pubmed-author:COLATE study group,
pubmed-author:ClumeckNathanN,
pubmed-author:DellamonicaPierreP,
pubmed-author:DragstedUlrik BUB,
pubmed-author:GerstoftJanJ,
pubmed-author:GuoY EYE,
pubmed-author:HillAndrewA,
pubmed-author:KatlamaChristineC,
pubmed-author:KjaerJesperJ,
pubmed-author:LundgrenJens DJD,
pubmed-author:MathiesenLarsL,
pubmed-author:PhillipsAndrew NAN,
pubmed-author:YouleMikeM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
761-70
|
|
pubmed:dateRevised |
2009-6-26
|
|
pubmed:meshHeading |
pubmed-meshheading:17310820-Anti-HIV Agents,
pubmed-meshheading:17310820-Drug Administration Schedule,
pubmed-meshheading:17310820-Drug Therapy, Combination,
pubmed-meshheading:17310820-Female,
pubmed-meshheading:17310820-HIV Infections,
pubmed-meshheading:17310820-HIV Reverse Transcriptase,
pubmed-meshheading:17310820-HIV-1,
pubmed-meshheading:17310820-Humans,
pubmed-meshheading:17310820-Lamivudine,
pubmed-meshheading:17310820-Male,
pubmed-meshheading:17310820-Mutation,
pubmed-meshheading:17310820-RNA, Viral,
pubmed-meshheading:17310820-Reverse Transcriptase Inhibitors,
pubmed-meshheading:17310820-Treatment Failure,
pubmed-meshheading:17310820-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
|
|
pubmed:affiliation |
Copenhagen HIV Programme (CHIP), Hvidovre University Hospital, Copenhagen, Denmark.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase IV
|
